Current status, of the Arilvax™ yellow fever vaccine

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax™ by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax™ in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalExpert Review of Vaccines
Volume3
Issue number4
DOIs
StatePublished - Aug 2004

Fingerprint

Yellow Fever Vaccine
Vaccines
Viral Hemorrhagic Fevers
Yellow Fever
Attenuated Vaccines
Licensure
Antiviral Agents
Liver Diseases
Immunity
Vaccination
Public Health
Clinical Trials
Kidney
Therapeutics

Keywords

  • 17D
  • Arilvax
  • Live attenuated vaccine
  • Yellow fever

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Current status, of the Arilvax™ yellow fever vaccine. / Barrett, Alan.

In: Expert Review of Vaccines, Vol. 3, No. 4, 08.2004, p. 413-420.

Research output: Contribution to journalArticle

@article{ed79c46f82c44b2b9cf8563c066b2651,
title = "Current status, of the Arilvax™ yellow fever vaccine",
abstract = "Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax™ by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax™ in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.",
keywords = "17D, Arilvax, Live attenuated vaccine, Yellow fever",
author = "Alan Barrett",
year = "2004",
month = "8",
doi = "10.1586/14760584.3.4.413",
language = "English (US)",
volume = "3",
pages = "413--420",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Current status, of the Arilvax™ yellow fever vaccine

AU - Barrett, Alan

PY - 2004/8

Y1 - 2004/8

N2 - Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax™ by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax™ in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.

AB - Yellow fever is a viral hemorrhagic fever that involves dysfunction of the liver and kidneys. There is no antiviral therapy available and vaccination is a major strategy in the control of this important public health problem. Yellow fever vaccine is a live attenuated vaccine, strain 17D, which is very safe and efficacious and induces long-term protective immunity in vaccinees. The vaccine is produced by six manufacturers worldwide, including Arilvax™ by Chiron vaccines (CA, USA) that is marketed in at least ten countries. Acambis (MA, USA) have acquired the rights to sell and market Arilvax™ in the USA, and have undertaken three clinical trials to obtain data for a Biological License Application that should proceed in 2005.

KW - 17D

KW - Arilvax

KW - Live attenuated vaccine

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=4043117698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043117698&partnerID=8YFLogxK

U2 - 10.1586/14760584.3.4.413

DO - 10.1586/14760584.3.4.413

M3 - Article

VL - 3

SP - 413

EP - 420

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 4

ER -